CliffBio
small molecule

STIMATE

DESMOPRESSIN ACETATE

Loss of exclusivity—loss of exclusivity
CompanyFerring Pharmaceuticals →See this company's full patent-cliff portfolio

Drug detail

Brand nameSTIMATE
Active ingredientDESMOPRESSIN ACETATE
Strength0.15MG/SPRAY
Dosage formSPRAY, METERED
RouteNASAL
ModalitySmall molecule
FDA approvalMarch 1994
Marketing statusDISCN

More from Ferring Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.

STIMATE patent cliff — loss of exclusivity — | CliffBio